文献速递心脑血管急症重症综合管理与镇静镇痛

急性单发皮层下梗死早期与延迟降压治疗的比较:CATIS-2随机临床试验二次分析

Early vs Delayed Antihypertensive Treatment in Acute Single Subcortical Infarction: A Secondary Analysis of the CATIS-2 Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-08-01
一句话结论在急性单发皮层下梗死合并责任动脉病变狭窄的患者中,早期降压与90天功能依赖或死亡风险增加相关(23.4% vs 7.7%;OR 3.67)。

本文为CATIS-2随机临床试验的二次分析,纳入中国106家医院2018年6月至2022年7月收治的997例弥散加权成像证实的急性单发皮层下梗死患者,比较早期(立即)与延迟(第8天开始)降压治疗与90天功能依赖或死亡(改良Rankin量表评分≥3分)的关系。全部患者中两组主要结局无显著差异(8.8% vs 7.1%;OR 1.25;P=0.34)。合并责任动脉病变狭窄者早期降压主要结局风险升高(23.4% vs 7.7%;OR 3.67;P=0.03),不合并者无此现象(6.6% vs 7.1%;OR 0.93;P=0.77),交互作用P=0.04。作者认为需按责任动脉病变情况个体化血压管理。

要点

  • 全部单发皮层下梗死患者中,早期与延迟降压的90天功能依赖或死亡无显著差异(8.8% vs 7.1%;OR 1.25,95%CI 0.79-1.99;P=0.34)。
  • 合并责任动脉病变狭窄者,早期降压较延迟降压增加90天功能依赖或死亡风险(23.4% vs 7.7%;OR 3.67,95%CI 1.14-11.86;P=0.03)。
  • 不合并责任动脉病变狭窄者,早期与延迟降压的主要结局无显著差异(6.6% vs 7.1%;OR 0.93,95%CI 0.55-1.57;P=0.77)。
  • 治疗与责任动脉病变狭窄存在显著交互作用(交互作用P=0.04),提示降压时机效应因是否合并狭窄而异。
  • 997例中合并责任动脉病变狭窄者116例(11.6%),不合并者881例(88.4%)。

适用人群与场景

  • CATIS-2试验纳入症状发作24至48小时内、收缩压升高的急性缺血性卒中患者;本分析纳入其中弥散加权成像检出单发皮层下梗死的997例(平均[SD]年龄62.4[9.8]岁;612例[61.4%]为男性)。
  • 按是否合并责任动脉病变狭窄分为两组:合并狭窄者116例(11.6%),不合并者881例(88.4%)。

诊断标准与关键阈值

  • 单发皮层下梗死:弥散加权成像检出。
  • 责任动脉病变狭窄:按原文分组条件分为合并与不合并。
  • 主要结局:90天功能依赖或死亡,定义为改良Rankin量表评分≥3分。

处置流程与药物剂量

  • 早期(立即)降压治疗与延迟(第8天开始)降压治疗为CATIS-2的两种干预策略。

研究设计与关键结果

  • 研究类型:CATIS-2随机临床试验的二次分析;纳入中国106家医院2018年6月至2022年7月收治的997例单发皮层下梗死患者;暴露为早期(立即)与延迟(第8天开始)降压治疗。
  • 全部单发皮层下梗死患者中,早期与延迟降压的主要结局无显著差异(8.8% vs 7.1%;OR 1.25,95%CI 0.79-1.99;P=0.34)。
  • 合并责任动脉病变狭窄者中,早期降压较延迟降压增加主要结局风险(23.4% vs 7.7%;OR 3.67,95%CI 1.14-11.86;P=0.03)。
  • 不合并责任动脉病变狭窄者中,早期与延迟降压的主要结局无显著差异(6.6% vs 7.1%;OR 0.93,95%CI 0.55-1.57;P=0.77)。
  • 主要结局的治疗与责任动脉病变狭窄交互作用显著(交互作用P=0.04)。
  • 统计分析于2023年7月至2024年5月进行;试验注册号ClinicalTrials.gov NCT03479554。

证据类型、等级与局限

  • 证据类型:随机临床试验的二次分析(post hoc亚组分析)。
  • 局限:原文报告需进一步研究以按责任动脉病变情况个体化血压管理。

对床旁实践的改变

  • 作者认为,在合并责任动脉病变狭窄的单发皮层下梗死患者中,与延迟降压相比,早期降压与90天功能依赖或死亡风险增加相关,需按责任动脉病变情况个体化血压管理。

指南或共识出处

  • China Antihypertensive Trial in Acute Ischemic Stroke II(CATIS-2)随机临床试验;试验注册号NCT03479554。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) suggests that early antihypertensive treatment did not reduce the risk of dependency or death in acute ischemic stroke (AIS), compared with delayed treatment. Single subcortical infarction (SSI) is an important stroke subtype, and the association of antihypertensive timing with clinical outcomes is unclear.

OBJECTIVE: To investigate the association of early vs delayed antihypertensive treatment with clinical outcomes in patients with SSI, stratified by the presence of parent artery disease (PAD) stenosis.

DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the CATIS-2 randomized clinical trial included 106 hospitals in China between June 2018 and July 2022. In CATIS-2, patients with AIS within 24 to 48 hours of symptoms onset and elevated systolic blood pressure were eligible. Patients with SSI detected in diffusion-weighted imaging were included in the current post hoc subgroup analysis. Patients were grouped into (1) SSI with PAD stenosis and (2) SSI without PAD stenosis. Statistical analysis was performed from July 2023 to May 2024.

EXPOSURES: Early (immediate) vs delayed (starting on day 8) antihypertensive therapy.

MAIN OUTCOME AND MEASURE: Primary outcome was the combination of functional dependency or death (modified Rankin Scale score ≥3) at 90 days.

RESULTS: Among 997 patients with SSI in CATIS-2 (mean [SD] age, 62.4 [9.8] years; 612 [61.4%] men), 116 (11.6%) had SSI with PAD and 881 (88.4%) had SSI without PAD. There was no significant difference in the primary outcome between early and delayed antihypertensive treatment groups among all patients with SSI (8.8% vs 7.1%; OR, 1.25 [95% CI, 0.79-1.99]; P = .34). Among patients with SSI with PAD, early antihypertensive treatment was associated with increased risk of the primary outcome compared with delayed treatment (23.4% vs 7.7%; OR, 3.67 [95% CI, 1.14-11.86]; P = .03); this finding was not observed in patients with SSI without PAD (6.6% vs 7.1%; OR, 0.93 [95% CI, 0.55-1.57]; P = .77). Significant interaction with treatment and presence of PAD stenosis was detected for the primary outcome (P for interaction = .04).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, early antihypertensive treatment was associated with an increased risk of functional dependency or death at 90 days among patients with SSI and coexisting PAD stenosis, compared with delayed antihypertensive treatment. Further studies are warranted for individualized BP management in patients with SSI by the presence of PAD.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03479554.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Wei Y, Xie X, Pan Y, et al. Early vs Delayed Antihypertensive Treatment in Acute Single Subcortical Infarction: A Secondary Analysis of the CATIS-2 Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39212990. doi:10.1001/jamanetworkopen.2024.30820

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。